Posted by Michael Wonder on 20 Jan 2022
Pathogenomix granted FDA breakthrough device designation
19 January 2022 - Patho-Seq uses next generation sequencing to rapidly identify bacteria from human samples during dangerous and life-threatening infections.
Pathogenomix announced that the US FDA has granted it a breakthrough device designation for its Patho-Seq assay.
